Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 10.23 USD 0.89%
Market Cap: 985.8m USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Net Margin
Avadel Pharmaceuticals PLC

-52.5%
Current
-957%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-52.5%
=
Net Income
-72.6m
/
Revenue
138.2m

Net Margin Across Competitors

Country IE
Market Cap 985.5m USD
Net Margin
-53%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.2B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.2B USD
Net Margin
17%
Country US
Market Cap 251.2B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.1B USD
Net Margin
7%
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
985.5m USD
Industry
Pharmaceuticals
Economic Moat
None

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
18.02 USD
Undervaluation 43%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-52.5%
=
Net Income
-72.6m
/
Revenue
138.2m
What is the Net Margin of Avadel Pharmaceuticals PLC?

Based on Avadel Pharmaceuticals PLC's most recent financial statements, the company has Net Margin of -52.5%.